Who Exports Ceftriaxone from India — 850 Suppliers Behind a $285.4M Market
India's ceftriaxone export market is supplied by 850 active exporters who collectively shipped $285.4M across 11,257 shipments. INNOVA CAPTAB LIMITED leads with a 12.7% market share, followed by UNIVENTIS MEDICARE LIMITED and UNILINK PHARMA PRIVATE LIMITED. The top 5 suppliers together control 31.3% of total export value, reflecting a moderately competitive market structure.
Top Ceftriaxone Exporters from India — Ranked by Export Value
INNOVA CAPTAB LIMITED is the leading ceftriaxone exporter from India, holding a 12.7% share of the $285.4M market across 11,257 shipments from 850 exporters. The top 5 suppliers — INNOVA CAPTAB LIMITED, UNIVENTIS MEDICARE LIMITED, UNILINK PHARMA PRIVATE LIMITED, AUROBINDO PHARMA LTD, MEDCELL PHARMA — collectively control 31.3% of total export value, indicating a competitive market. Individual shares are: INNOVA CAPTAB LIMITED (12.7%), UNIVENTIS MEDICARE LIMITED (5.4%), UNILINK PHARMA PRIVATE LIMITED (4.9%), AUROBINDO PHARMA LTD (4.6%), MEDCELL PHARMA (3.7%).
Top Ceftriaxone Exporters from India
Ranked by export value · 850 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | INNOVA CAPTAB LIMITED ROXONE 1GM: (CEFTRIAXONE INJECTION USP 1CEFTRORID 1G (CEFTRIAXONE FOR INJECTIONCEFIPO-1G INJ (CEFTRIAXONE FOR INJECTION | $36.2M | 20 | 12.7% |
| 2 | UNIVENTIS MEDICARE LIMITED CEFIPO-1G INJ (CEFTRIAXONE FOR INJECTIONCEFONE INJECTION 1000MG (CEFTRIAXONE FORVENTICEF 1000MG (CEFTRIAXONE FOR INJECTI | $15.4M | 1 | 5.4% |
| 3 | UNILINK PHARMA PRIVATE LIMITED CEFTRIAXONE INJECTION USP 1G (CEFTRIAONECEFTRIAXONE INJECTION USP 1G -162400 NOS | $13.9M | 5 | 4.9% |
| 4 | AUROBINDO PHARMA LTD ROXONE 1GM: (CEFTRIAXONE INJECTION USP 1CEFTRIAXONE FOR INJECTION 1G(AUROVIAX 10TRAXICOLL (CEFTRIAXONE FOR INJECTION USP | $13.3M | 6 | 4.6% |
| 5 | MEDCELL PHARMA CEFTRORID 1G (CEFTRIAXONE FOR INJECTIONCEFIPO-1G INJ (CEFTRIAXONE FOR INJECTIONCOMBIPACK OF CEFTRIAXONE FOR INJECTION U | $10.7M | 5 | 3.7% |
| 6 | LINCOLN PHARMACEUTICALS LTD ROXONE 1GM: (CEFTRIAXONE INJECTION USP 1CEFIPO-1G INJ (CEFTRIAXONE FOR INJECTIONCOMBIPACK OF CEFTRIAXONE FOR INJECTION U | $8.8M | 13 | 3.1% |
| 7 | SAKAR HEALTHCARE LIMITED ROXONE 1GM: (CEFTRIAXONE INJECTION USP 1CEFTRIAXONE INJECTION USP 1G (CEFTRIAONECEFIPO-1G INJ (CEFTRIAXONE FOR INJECTION | $7.7M | 16 | 2.7% |
| 8 | INJECT CARE PARENTERALS PRIVATE LIMITED ROXONE 1GM: (CEFTRIAXONE INJECTION USP 1STERILE CEFTRIAXONE SODIUM USP INJECTIONCIPLACEF 1000 INJECTION 1GM | $6.9M | 14 | 2.4% |
| 9 | CIPLA LIMITED CEFTRIAXONE INJECTION USP 1G (CEFTRIAONECEFTRORID 1G (CEFTRIAXONE FOR INJECTIONCIPLACEF 1000 INJECTION 1GM | $6.7M | 5 | 2.3% |
| 10 | THEON PHARMACEUTICALS LIMITED ROXONE 1GM: (CEFTRIAXONE INJECTION USP 1COMBIPACK OF CEFTRIAXONE FOR INJECTION UCOMBIPACK OF CEFTRIAXONE & SULBACTAM FOR | $6.3M | 14 | 2.2% |
| 11 | SCOTT EDIL PHARMACIA LIMITED ROXONE 1GM: (CEFTRIAXONE INJECTION USP 1CEFTRORID 1G (CEFTRIAXONE FOR INJECTIONCEFIPO-1G INJ (CEFTRIAXONE FOR INJECTION | $5.7M | 30 | 2.0% |
| 12 | SCOTT-EDIL ADVANCE RESEARCH LABORATORIES & EDUCATI CEFTRORID 1G (CEFTRIAXONE FOR INJECTIONCEFIPO-1G INJ (CEFTRIAXONE FOR INJECTIONCEFONE INJECTION 1000MG (CEFTRIAXONE FOR | $5.0M | 9 | 1.7% |
| 13 | NECTAR LIFE SCIENCES LIMITED ROXONE 1GM: (CEFTRIAXONE INJECTION USP 1CEFTRIAXONE INJECTION USP 1G (CEFTRIAONECEFTRIAXONE FOR INJECTION 1G(AUROVIAX 10 | $4.9M | 15 | 1.7% |
| 14 | SWISS PARENTERALS LIMITED CEFTRIAXONE FOR INJECTION 1G(AUROVIAX 10TRAXICOLL (CEFTRIAXONE FOR INJECTION USPTRAXICOLL CEFTRIAXONE FOR INJECTION USP | $4.6M | 22 | 1.6% |
| 15 | VENUS REMEDIES LIMITED ROXONE 1GM: (CEFTRIAXONE INJECTION USP 1CEFTRIAXONE INJECTION USP 1G (CEFTRIAONECEFIPO-1G INJ (CEFTRIAXONE FOR INJECTION | $4.0M | 30 | 1.4% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Ceftriaxone exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| AUROBINDO PHARMA LTD | Approved | Yes | Yes | Multiple | Aurobindo Pharma Ltd has multiple FDA approvals and WHO-GMP certifications. |
| CIPLA LIMITED | Warning Letter with March | Yes | Yes | Multiple | Cipla Limited received an FDA warning letter in March 2020 but holds WHO-GMP and |
| THEON PHARMACEUTICALS LIMITED | Not Listed | Yes | No | Not Listed | Theon Pharmaceuticals Limited holds a WHO-GMP certification. |
| UNILINK PHARMA PRIVATE LIMITED | Not Listed | Yes | No | Not Listed | Unilink Pharma Private Limited holds a WHO-GMP certification. |
| VENUS REMEDIES LIMITED | Not Listed | Yes | No | Not Listed | Venus Remedies Limited holds a WHO-GMP certification. |
TransData Nexus reviewed the regulatory standing of 5 leading Ceftriaxone exporters from India. 1 hold US FDA facility approvals, 5 maintain WHO-GMP certification, and 2 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Ceftriaxone sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal hub for active pharmaceutical ingredients (APIs) and bulk drug manufacturing. The city hosts Genome Valley, India's first biotech cluster, and is home to over 800 pharmaceutical companies, including major players like Aurobindo Pharma Ltd., which contributed $13.3 million (4.6%) to Ceftriaxone exports during the specified period. The region's advanced R&D infrastructure and skilled workforce make it a significant contributor to India's pharmaceutical exports.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production and houses companies such as Lincoln Pharmaceuticals Ltd., which accounted for $8.8 million (3.1%) of Ceftriaxone exports. The region's robust infrastructure, including ports and transportation networks, supports efficient manufacturing and distribution of pharmaceutical products.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for India's pharmaceutical industry. Mumbai, being the financial capital, provides access to international markets and regulatory bodies. Cipla Limited, headquartered in Mumbai, exported Ceftriaxone worth $6.7 million (2.3%) during the analyzed period. The region's strategic location and well-established logistics infrastructure facilitate seamless export operations.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as a prominent pharmaceutical manufacturing zone, largely due to favorable tax incentives and supportive government policies. The area hosts over 1,000 pharmaceutical units, making it Asia's largest pharmaceutical hub. Companies like Cipla have established manufacturing plants in Baddi, leveraging the region's cost advantages and skilled labor force.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Evaluate Supplier Capabilities: Assess the manufacturing capabilities and compliance standards of suppliers, especially those in Hyderabad and Ahmedabad-Vadodara, to ensure consistent quality and supply.
- Leverage Export Hubs: Utilize the Mumbai-Thane-Raigad region's export infrastructure for efficient international distribution of Ceftriaxone.
- Consider Cost Advantages: Explore partnerships with manufacturers in Baddi-Nalagarh to benefit from tax incentives and lower production costs.
By strategically sourcing from these diverse pharmaceutical clusters, companies can enhance supply chain resilience and optimize the procurement of Ceftriaxone.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Ceftriaxone exporters from India
Innova Captab Limited — Innova Captab acquires Sharon Bio-Medicine Limited
In June 2023, Innova Captab Limited, through its wholly owned subsidiary Univentis Medicare Limited, completed the acquisition of Sharon Bio-Medicine Limited. This acquisition was finalized following the approval of a resolution plan by the National Company Law Tribunal, Mumbai Bench, on May 17, 2023. - IMPACT: The acquisition is expected to enhance Innova Captab's manufacturing capabilities, potentially increasing Ceftriaxone production and export capacity.
Impact: The acquisition is expected to enhance Innova Captab's manufacturing capabilities, potentially increasing Ceftriaxone production and export capacity.
Common Questions — Ceftriaxone Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which ceftriaxone supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, INNOVA CAPTAB LIMITED leads with 600 recorded shipments worth $36.2M. UNIVENTIS MEDICARE LIMITED (111 shipments) and UNILINK PHARMA PRIVATE LIMITED (26 shipments) are also established high-volume exporters.
Q How many ceftriaxone manufacturers are there in India?
India has 850 active ceftriaxone exporters with a combined export market of $285.4M across 11,257 shipments to 162 countries. The top 5 suppliers hold 31.3% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for ceftriaxone from India?
Average FOB unit price: $3.73 per unit, ranging from $0.00 to $914.87. Average shipment value: $25.4K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 850 verified Indian exporters of Ceftriaxone ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 11,257 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 162 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
11,257 Verified Shipments
850 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists